Health Care · Pharmaceutical Preparations

OPK OPKO HEALTH, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 94480986 filings
Russell 2000

OPK at a glance

OPKO HEALTH, INC. (OPK, SEC CIK 944809) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), OPKO HEALTH, INC. (OPK) reported revenue of $606.9 million (down 14.9% from FY2024) and a net loss of $225.7 million. Diluted EPS was -$0.30.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding OPKO HEALTH, INC. (OPK) shares worth $163.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by PAGANELLI JOHN A on November 5, 2026 of 9,175 shares at $1.82 per share.
  • In the last 90 days, OPK insiders reported 0 open-market purchases ($0) and 2 open-market sales ($25K) on Form 4, a net sale of $25K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$606.9M
−14.9% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$25K
13F holders
29 funds
$163.6M · +2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $65.4M, up 16% YoY from $56.4M, driven by Eli Lilly royalties and Rayaldee sales
  • Operating loss $31.4M vs $33.6M YoY, equivalent margins of -48.0% vs -59.5%
  • Best segment Global Products: revenue $48.4M, operating income $6.0M vs loss $1.2M
  • Worst segment Innovative Biotech: operating loss $26.8M vs $22.5M, R&D $30.4M vs $26.3M
  • Cash, equivalents and restricted cash $403.2M; operating cash use $99.1M and royalty-note proceeds $123.1M YTD
  • Outlook: liquidity expected sufficient beyond 12 months, with risks from pipeline spending, clinical milestones, financing needs and tariffs

Risk Factors

  • No material changes to risk factors from the most recent Form 10-K
  • Key carried-forward risks remain those disclosed in the Form 10-K, without quarterly updates

AI summary of the OPK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers OPKO’s Q3 2026 operating and financial results for the quarter ended September 30, 2026
  • Conference call scheduled for business updates, financial results discussion and financial guidance

Item EX-99.1: Item EX-99.1

  • Q3 continuing-operations revenue $65.4M, up 16%, while net loss widened to $35.5M, or $0.05 per share
  • Labcorp deal offers $722M upfront plus up to $150M tied to 4Kscore sales, pending approvals and closing conditions
Filed Oct 15, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • OPKO agreed to sell BioReference testing assets to Labcorp for $722 million cash at closing
  • Additional consideration up to $150 million over 10 years tied to 4Kscore prostate test revenue
Filed Oct 2, 2026Full analysis →

Item 8.01: Other Events

  • $121 million of 3.75% convertible notes became convertible through December 31, 2026
  • Conversion triggered after OPKO shares exceeded $1.495, or 130% of the $1.15 conversion price

AI summaries of OPK 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OPK

Don't miss the next OPK filing

  • Alerts as it files. A push when OPK files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OPK, by share count.
  • Ask anything. An AI agent that reads every OPK filing and answers with sources.

OPK alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
PAGANELLI JOHN ASellNov 5, 2026$1.82
PAGANELLI JOHN ASellNov 5, 2026$1.78
Logal AdamFJul 24, 2026$1.22
Rubin Steven DFJul 24, 2026$1.22
PAGANELLI JOHN AAJun 18, 2026-
Lachman Prem AAJun 18, 2026-
UPPALURI SUBBARAO VAJun 18, 2026-
PFENNIGER RICHARD C JRAJun 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$713.1M$606.9M
Gross Profit$318.1M$218.5M$205.9M
Operating Income--$152.1M-$117.4M
Net Income-$188.9M-$53.2M-$225.7M
Gross Margin-30.6%33.9%
Op. Margin--21.3%-19.3%
Net Margin--7.5%-37.2%
Balance Sheet
Total Assets$2.0B$2.2B$1.9B
Equity-$1.4B$1.3B
ROE--3.9%-17.8%
Per Share
EPS-$-0.08$-0.30
Cash Flow
Operating CF-$28.2M-$183.5M-$178.5M

Source: XBRL data in OPKO HEALTH, INC. (OPK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OPK share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OPK shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$163.6M
Q2 202627$147.8M
Q1 202627$110.5M
Q4 202528$124.3M
Q3 202527$152.9M
Q2 202527$130.7M
Q1 202525$130.3M
Q4 202422$87.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OPK filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 5, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 15, 2026Analysis-
8-KOct 2, 2026Analysis-
8-KAug 14, 2026Analysis-
SC 13DAug 7, 2026-
4Jul 28, 2026--
4Jul 28, 2026--
10-QJul 27, 2026Analysis
8-KJul 27, 2026Analysis-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 18, 2026Analysis-
10-QApr 28, 2026Analysis
8-KApr 28, 2026Analysis-
4Mar 20, 2026--
4Mar 20, 2026--
8-KMar 19, 2026Analysis-
10-KFeb 26, 2026-
8-KFeb 26, 2026Analysis-

Related Health Care companies

All Health Care →

OPK SEC filings: frequently asked questions

Are OPK insiders buying or selling?

In the last 90 days, OPKO HEALTH, INC. (OPK) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $24,577 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OPK stock?

As of September 30, 2026, the largest OPKO HEALTH, INC. (OPK) holders among the 13F filers tracked by SignalX were BlackRock ($59.3 million), Vanguard Capital Management LLC ($23.9 million), Vanguard Portfolio Management LLC ($23.6 million), State Street Corp ($17.2 million), Goldman Sachs Group ($12.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OPK's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), OPKO HEALTH, INC. (OPK) reported revenue of $606.9 million (down 14.9% from FY2024) and a net loss of $225.7 million. Diluted EPS was -$0.30. The figures come from the XBRL data in the 10-K.

What did OPK report in its latest 8-K?

OPKO HEALTH, INC. (OPK) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers OPKO’s Q3 2026 operating and financial results for the quarter ended September 30, 2026.

What are the latest OPK SEC filings?

OPKO HEALTH, INC. (OPK) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 5, 2026.

What is OPK's SEC CIK number?

OPKO HEALTH, INC. (OPK)'s SEC Central Index Key (CIK) is 944809. EDGAR lists every OPK filing under that number.

Ask anything about OPK

The research agent reads OPK's filings, financials, insider trades and 13F holders, then answers with sources.